Rigel Pharmaceuticals (RIGL) investor relations material

Transformational growth strategy

• Focused on expanding the commercial business, in-licensing late-stage assets, maintaining financial discipline, and advancing the development pipeline.

• Progressed from one commercial product in 2020 to three by 2025, with four expected in the 2030s.

• Achieved profitability since Q3 2024 and increased cash by over $100 million through 2025.

Commercial portfolio and performance

• Q1 2026 net product sales reached $54.9M, a 26% increase over Q1 2025, led by TAVALISSE, GAVRETO, and REZLIDHIA.

• TAVALISSE showed 31% sales growth, GAVRETO 7%, and REZLIDHIA 31% year-over-year.

• TAVALISSE is indicated for chronic immune thrombocytopenia, with significant market share opportunities in later lines of therapy.

• REZLIDHIA targets relapsed/refractory AML with IDH1 mutation, addressing a significant unmet need.

• GAVRETO is approved for RET fusion-positive NSCLC and thyroid cancer, with strong coverage and a differentiated value proposition.

In-licensing and business development

• Acquired global rights to VEPPANU (vepdegestrant), the first FDA-approved oral PROTAC for ER+/HER2-, ESR1-mutated metastatic breast cancer, in May 2026.

• VEPPANU is expected to become the largest revenue producer and transform the commercial portfolio.

• The license agreement included a $70M upfront payment, $15M in transition payments, and up to $320M in milestones.

• Previous acquisitions include REZLIDHIA (2022) and GAVRETO (2024), expanding the oncology portfolio.